Case Report: Response to crizotinib treatment in a patient with advanced non-small cell lung cancer with LDLR-ROS1 fusion

Case Report: Response to crizotinib treatment in a patient with advanced non-small cell lung cancer with LDLR-ROS1 fusion

C-ros oncogene 1 (ROS1) fusion is a pathogenic driver gene in non-small cell lung cancer (NSCLC). Currently, clinical guidelines from the National Comprehensive Cancer Network (NCCN) have recommended molecular pathologic tests for patients with NSCLC, including the detection of the ROS1 gene. Crizot...

Full description

Bibliographic Details
Main Authors: Yun Shu, Zhouyu Wang, Hongjuan Shang, Wei Le, Yan Lei, Longzhang Huang, Liming Tao, Jun Chen, Jing Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-04-01
Series:Frontiers in Oncology
Subjects:
advanced non-small cell lung cancer
c-ros oncogene 1
LDLR-ROS1 fusion
crizotinib
next-generation sequencing
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1169876/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1169876/full

Similar Items